40 results about "Apoptotic gene" patented technology

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.

The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.

The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.

The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.

The requirement of T cell activation for efficient expression of genes after messenger ribonucleic acid (mRNA) transfection is leveraged to identify and enrich antigen-specific T cells responding to antigen-pulsed dendritic cells (DCs). RNA transfection of marker genes is used for the selection and enrichment of antigen-specific T cells for use in adoptive immunotherapy. RNA-modified T cells are also used for the generation of enhanced effector populations for use in adoptive immunotherapy. Genes whose transient expression may significantly enhance the in vivo function of T cells (i.e., migratory receptors, anti-apoptotic genes or cytokines enhancing T cell proliferation / differentiation) are used in this modality.

The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.

The invention discloses a lentivirus expression vector. The lentivirus expression vector comprises a gene encoding a chimeric antigen receptor and an iCasp9 apoptotic gene. The invention also discloses a CD19-CAR-T cell carrying an iCasp9 suicide gene. The CD19-CAR-T cell is a T lymphocyte comprising a lentivirus expression vector or a T lymphocyte of which the chromosome is integrated with a gene encoding a chimeric antigen receptor and an iCasp9 apoptotic gene. The invention also discloses a use of the CD19-CAR-T cell carrying an iCasp9 suicide gene in preparation of drugs for preventing and / or treating and / or assistantly treating cancers. Compared with the existing CD19-CAR-T cell, the CD19-CAR-T cell carrying an iCasp9 suicide gene utilizes a suicide mechanism and can express CAR and co-express a suicide gene iCasp9. When serious side effects occur, through inducing T cell apoptosis, CRS side effects are controlled and safety is improved.

The invention belongs to the field of medicament synthesis, and relates to Danshensu derivatives with a structure in the following formula, a synthesis method thereof, and application thereof in pharmacy. The synthesis method adopts a chiral synthesis method to synthesize the Danshensu derivatives with stable structures in high yield, in particular derivatives of dextrorotatory Danshensu with high optical purity. Through experiments of animal models with hypoxic myocardial cells, results show that the Danshensu derivatives can reduce LDH leakage of the hypoxic myocardial cells, improve the activity of hyperoxide dismutase in the cells, inhibit generation of a product of lipid peroxidation, promote the expression of anti-apoptotic gene bcl-2 mRNA and inhibit the expression of pro-apoptosisgene bax mRNA and apoptotic gene caspase-3mRNA; and the results prove that the Danshensu derivatives have an effect of protecting hypoxic cardiac muscle and can be used for preparing medicaments for treating ischemic heart disease.

The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.

An immunotherapeutic strategy is disclosed that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death. Gene gun delivery (particle bombardment) of siRNA specific for Bak and / or Bax to antigen-expressing DCs prolongs the lives of such DCs and lead to enhanced generation of antigen-specific CD8+ T cell-mediated immune responses in vivo. Similarly, antigen-loaded DC's transfected with siRNA targeting Bak and / or Bax serve as improved immunogens and tumor immunotherapeutic agents.

Nucleic acid compositions encoding a pro-apoptotic protein, Bok (Bcl-2-related ovarian killer) are identified. Bok has conserved Bcl-2 homology domains 1, 2 and 3 and a C-terminal transmembrane region present in other Bcl-2 related proteins, but lacks the BH4 domain found only in anti-apoptotic Bcl-2 proteins. Over-expression of Bok induces apoptosis. Cell killing induced by Bok is suppressed by co-expression with selective anti-apoptotic Bcl-2 proteins. Bok is highly expressed in the ovary, testis and uterus, particularly in granulosa cells, the cell type that undergoes apoptosis during follicle atresia. Identification of Bok as a new pro-apoptotic protein with wide tissue distribution and hetero-dimerization properties facilitates elucidation of apoptosis mechanisms in reproductive and other tissues, and provides a means for manipulating apoptosis.

The present invention relates to the cross-species transfer of apoptosis genes to plant cells, the transgenic plants produced thereby, and screening assays using these plants. The present invention also relates to drug discovery screening methods utilizing transgenic plant cells. In addition, the present invention relates to methods for identifying components of the apoptotic pathway in plant cells using non-plant proteins and nucleic acids.

An immunotherapeutic strategy is disclosed that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death. Gene gun delivery (particle bombardment) of siRNA specific for Bak and / or Bax to antigen-expressing DCs prolongs the lives of such DCs and lead to enhanced generation of antigen-specific CD8+ T cell-mediated immune responses in vivo. Similarly, antigen-loaded DC's transfected with siRNA targeting Bak and / or Bax serve as improved immunogens and tumor immunotherapeutic agents.

The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.

The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell expressing recombinant Factor VIII such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of recombinant Factor VIII by expressing one or more anti-apoptotic polypeptides in a cell such that production of recombinant Factor VIII by the cell is increased. Recombinant cells useful for producing Factor VIII.

The present invention provides transgenic algal cells resistant to programmed cell death (PCD) and methods and compositions useful in generating such cells. Specifically, the invention utilizes expression of one or more mammalian anti-apoptotic genes in algal cells to promote resistance to PCD, which is useful for stress tolerance and increased cell viability and biomass production during cultivation.

The invention discloses a vector used for oriented screening of homologous recombination PGC, and a preparation method and an application thereof. According to the invention, expression cassette UAS: mRFP-UTRnos1 and expression cassette UAS: puma-UTRnos1 are connected in series, such that vector p (UAS: mRFP, UAS: puma) which can be used in oriented screening of homologous recombination PGC can be constructed. The sequence of the vector is represented by SEQ ID NO.1. The vector has fluorescent specific high-efficiency PGC marking function, and has pro-apoptotic gene PGC specific rejection function. P (UAS: mRFP, UAS: puma) is used as a vector frame, targeting gene homologous sequence left and right arms are respectively positioned on two sides of the expression cassette UAS: mRFP-UTRnos1, and the expression cassette UAS: puma-UTRnos1 is positioned on the outer side of the homologous sequence, such that a homologous recombination vector is prepared. The homologous recombination vector is introduced into a Tg (kop: KalTA4) embryo, and embryo expressing mRFP in PGC is selected, such that embryo subjected to homologous recombination germ cells is obtained.

The invention belongs to the field of medicament synthesis, and relates to Danshensu derivatives with a structure in the following formula, a synthesis method thereof, and application thereof in pharmacy. The synthesis method adopts a chiral synthesis method to synthesize the Danshensu derivatives with stable structures in high yield, in particular derivatives of dextrorotatory Danshensu with high optical purity. Through experiments of animal models with hypoxic myocardial cells, results show that the Danshensu derivatives can reduce LDH leakage of the hypoxic myocardial cells, improve the activity of hyperoxide dismutase in the cells, inhibit generation of a product of lipid peroxidation, promote the expression of anti-apoptotic gene bcl-2 mRNA and inhibit the expression of pro-apoptosisgene bax mRNA and apoptotic gene caspase-3mRNA; and the results prove that the Danshensu derivatives have an effect of protecting hypoxic cardiac muscle and can be used for preparing medicaments for treating ischemic heart disease.

Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and / or anti-apoptotic activity, such as compounds having anti-apoptotic activity, and such as compounds that induce, restore, or modulate apoptosis and / or inhibit, diminish, or modulate anti-apoptotic activity, methods of screening for such compounds, and methods of using such compounds in the therapeutic treatment of diseases; Methods of treating eukaryotic cells with compounds that regulate or modulate apoptosis and / or anti-apoptotic activity; Methods of enhancing the stability, growth, and / or productivity of eukaryotic cells; Pharmaceutical compositions that regulate or modulate apoptosis and / or anti-apoptotic activity.

The invention relates to the technical field of traditional Chinese medicine, and in particular, relates to an application of a traditional Chinese medicine composition in preparation of antidepressant drugs. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-15 parts of fructus aurantii, 4-8 parts of white atractylodes rhizome, 4-8 parts of rhizoma pinellinae praeparata, 5-15 parts of rhizoma coptidis, 3-7 parts of codonopsis pilosula, 2-6 parts of liquorice, 2-6 parts of poria cocos, 4-12 parts of cortex magnoliae officinalis, 2-6parts of malt, and 2-6 parts of dry ginger. Experiments show that the traditional Chinese medicine composition can improve the cell survival rate of a corticosterone-induced PC12 nerve cell injury model, restore the mitochondrial membrane potential, inhibit the expression of apoptotic genes and / or promote apoptosis and inhibit the gene expression; the traditional Chinese medicine composition significantly reduces the tail suspension immobility time and forced swimming immobility time of mice, and increases the serum 5-hydroxytryptamine content; the depressive behavior of the mice is improved obviously, and the results show that the composition has remarkable curative effect on depression.

The present invention belongs to a preparation method of PCADK composite microspheres encapsulating apoptotic genes. The preparation method comprises the following specific steps: (1) weighing 200 mgof PCADK in 2 mL of dichloromethane to obtain a PCADK dichloromethane solution which is used as an oil phase for a standby application; extracting 20 [mu]L of a plasmid solution containing apoptotic genes as an internal aqueous phase for a standby application, wherein plasmid concentration is 5 [mu]g / [mu]L; and measuring 60 mL of a PVA aqueous solution at a concentration of 1% as an external aqueous phase for a standby application; (2) slowing dropping 20 [mu]L of the plasmid solution into ice bath of the PCADK dichloromethane solution at a homogenizing condition of 13,500 rpm / min and continuing stirring for 2 min to obtain an emulsion; (3) continuously stirring the 1% PVA aqueous solution at 1,500 rpm / min, then dropping the obtained emulsion in the step (2) into the above PVA aqueous solution, continuing stirring, conducting evaporation to remove the dichloromethane, then conducting centrifugation, washing, vacuum freeze-drying and storing at -20 DEG C to obtain the PCADK composite microspheres encapsulating the apoptotic genes. The PCADK is used to encapsulate the plasmid having a therapeutic effect, realizes controlled delivery of the genes and improves gene transfection efficiency.

The invention belongs to the field of research and development of anti-radiation products, and particularly relates to a composition and application thereof in medicines / healthcare products for prevention and treatment of mobile phone radiation. The invention provides the composition. The invention also provides a preparation method of the composition. The invention also provides the application of the composition or a product obtained by the preparation method in anti-radiation medicines and / or healthcare products. In the composition, NADH and / or NADPH can maintain the normal level of anti-radiation active ingredients in the body and can also maintain the expression of pro-apoptotic genes and the normal expression of anti-apoptotic genes to relieve cell damage caused by electromagnetic radiation, and meanwhile other components have a synergistic effect with the NADH and / or NADPH to promote the repair effect; it is shown by animal tests that the radiation damage of tested animals is significantly reduced after dosing; the technical defects that in the prior art, anti-radiation products have a poor anti-radiation effect and cause adverse reactions to the human body are overcome.

The invention relates to a constructed carp apoptotic gene, a vector and application of the gene. From 5' to 3', the constructed carp apoptotic gene is sequentially composed of carp MT-1 promoter, caspase-8 small subunit (P10) coding sequence, caspase-8 large subunit (P20) coding sequence, and carp MT-1polyA signal sequence. The carp DNA vaccine vector of the invention includes a eukaryotic expression vector and an apoptotic gene of the above carp gene in the eukaryotic expression vector. The inductive apoptotic gene is constructed based on carp MT promoter and caspase-8, and after being inserted to pEGFP-N1 vector to construct 'suicide' DNA vaccine vector, the apoptotic gene may respond to the induction of the conditions such as metal ions (e.g., Zn2+) to express apoptosis of caspase-8 induced transfection cells and may apply to the preparation of carp DNA vaccines to further improve safety of DNA vaccines.

The invention discloses a lentivirus expression vector. The lentivirus expression vector comprises a gene encoding a chimeric antigen receptor and an iCasp9 apoptotic gene. The invention also discloses a CD19-CAR-T cell carrying an iCasp9 suicide gene. The CD19-CAR-T cell is a T lymphocyte comprising a lentivirus expression vector or a T lymphocyte of which the chromosome is integrated with a gene encoding a chimeric antigen receptor and an iCasp9 apoptotic gene. The invention also discloses a use of the CD19-CAR-T cell carrying an iCasp9 suicide gene in preparation of drugs for preventing and / or treating and / or assistantly treating cancers. Compared with the existing CD19-CAR-T cell, the CD19-CAR-T cell carrying an iCasp9 suicide gene utilizes a suicide mechanism and can express CAR and co-express a suicide gene iCasp9. When serious side effects occur, through inducing T cell apoptosis, CRS side effects are controlled and safety is improved.

The invention relates to the technical field of biological medicine preparations, in particular to application of Dencichine in preparation of a biological medicine preparation for treating lung cancer, and experiments show that Dencichine can remarkably inhibit tumor formation of lung cancer cells. Meanwhile, according to the application disclosed by the invention, Western blot detection finds that Denchinine can be used for remarkably inhibiting proliferation of A549 lung cancer cells and expression of invasion genes, but promoting expression of apoptosis genes of A549; cCK-8 detection shows that the Dencichine can be used for remarkably inhibiting the proliferation of the A549 cell; trans-well detection shows that the invasion of the A549 cell can be obviously inhibited by the Dencichine, and the invasion of the A549 cell can be obviously inhibited by the Dencichine; annexin-V / PI detection shows that the apoptosis of the A549 cell can be obviously promoted by the Dencichine. In a nude mouse experiment, the Dencichine obviously inhibits tumor formation of A549 under the skin of a nude mouse. Therefore, the Dencichine disclosed by the invention is expected to be used for developing medicine products for treating lung cancer.

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.

The invention discloses a cell apoptosis gene segment for reducing the egg laying amount of the small brown rice planthopper and application thereof. The gene sequence is shown as SEQ ID NO.1 and theamino acid sequence is shown as SEQ ID NO.2. According to the invention, dsRNA of a small brown rice planthopper cell apoptosis gene segment is synthesized through a molecular biological technique; and the egg laying amount is reduced obviously by using an egg laying amount and a gene capable of serving as an effective target for biological control of the small brown rice planthopper is found. ThedsRNA sequence for synthesizing the small brown rice planthopper cell apoptosis gene segment is shown as SEQ ID NO.5, so that the gene is effectively silenced and the degradation of RNA enzyme can bewell resisted. Meanwhile, the synthesis cost is low and thus the cell apoptosis gene segment is suitable for large-scale application and popularization; the dsRNA of the cell apoptosis gene of the small brown rice planthopper has a significant reduction effect on the egg laying amount of the small brown rice planthopper by the RNAi technology; and thus a novel path is provided for controlling pests through the RNAi technology and the use of chemical pesticides is reduced.

A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR / J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.